in our daily life, although many human greatness, but once the onset, will soon wither like a flower, especially the series of liver cancer, in the face of their assault, we need unity and cooperation of mutual defense. The fourth Shenzhen surgical forum held in 25 in Hong Kong hospital in Shenzhen, more than 200 surgical experts from the United States, Japan, South Korea, Hongkong and the mainland in the Hong Kong Hospital, the latest development in the technology exchange of hepatobiliary disease treatment.
conference announced by the University of Hong Kong hospital in Shenzhen led the establishment of the University of Hong Kong, Shenzhen hospital liver cancer therapy Alliance (hereinafter referred to as the "alliance"). At present, the first batch of union members a total of 10 hospitals are: Hong Kong, Shenzhen hospital, Shenzhen Chinese Traditional Medical Hospital, Pingshan New District People’s Hospital, Fuyong people’s Hospital, Shenzhen city occupation disease prevention and control center, Longhua District People’s Hospital, Guangming New District People’s Hospital of Yantian District, Second People’s Hospital, Baoan District maternal and child health hospital, maternal and Child Health Hospital of Yantian district.
The international authority of the minimally invasive pancreatic surgery expert MichaelLKendrick
from the Mayo Medical Center; international famous experts of pancreatic cancer AkimasaNakao Japan Nagoya Central Hospital; China Academy of science academician Chen Xiaoping, Chinese Tongji Hospital Affiliated to Sir Run Run Shaw Hospital affiliated to Huazhong University of Science and Technology; Cai Xiujun Dean of Zhejiang University school of medicine; University of Hong Kong and department director Professor Lu Chongmao, Dr. Chen Zhiren and other international big names appeared in the venue of surgery and share the latest advances in the treatment of hepatocellular carcinoma and how to break the boundaries of pancreatectomy.
It is reported that
, at present in the domestic liver cancer incidence ranked third, while Guangdong and Hongkong are Chinese hepatocellular carcinoma in high incidence areas of Shenzhen in 2015, the registration of new HCC cases more than 1500 cases of liver cancer, the situation is very serious. Surgical treatment of hepatocellular carcinoma is the best means of radical treatment, radical resection of liver cancer patients can be more than 5 years survival reached 50% of the world’s leading cancer centers, and early small hepatocellular carcinoma 5 years survival rate can reach above 90%.
in the face of liver cancer, how many people in our lives have been deprived of their lives, but with the progress of medical standards, hope to be able to effectively resist the invasion of cancer in the future. At the same time, in the treatment of mutual alliance, the Hong Kong Shenzhen hospital director Lu Chongmao Professor Dean, University of Hong Kong School of Surgery said, "University of Hong Kong sincerely hope that with the Hong Kong hospital in Shenzhen the first mainland platform, together with the surrounding Shenzhen hospital colleagues for liver surgery for patients with hepatocellular carcinoma and the level of progress together. After the establishment of the mutual aid Alliance for liver cancer in the Shenzhen Hospital of University of Hong Kong, we also welcome more hospitals to join the league."